国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
21期
2642-2644
,共3页
头孢唑肟钠%不良反应(ADR)%临床分析
頭孢唑肟鈉%不良反應(ADR)%臨床分析
두포서우납%불량반응(ADR)%림상분석
Ceftizoxime sodium%Adverse reactions%Clinical analysis
目的 通过对39例头孢唑肟钠注射剂引起的不良反应报告进行分析,探讨头孢唑肟钠注射剂不良反应发生的规律和临床表现,提示临床注意监测其不良反应,避免严重后果.方法 对39例头孢唑肟钠注射剂引起的不良反应进行统计和分析.结果 女22例,男17例,女性多于男性;患者年龄在0~50岁之间,其中10岁以下儿童发生率最高,为46.15%;静脉滴注给药38例(97.44%),肌内注射给药1例(2.56%);头孢唑肟钠注射剂的主要不良反应是过敏反应(66.67%),此外还可引起过敏性休克、呼吸系统损害等较少见的、严重的不良反应.结论 要合理使用头孢唑肟钠注射剂,避免和减少不良反应的发生.
目的 通過對39例頭孢唑肟鈉註射劑引起的不良反應報告進行分析,探討頭孢唑肟鈉註射劑不良反應髮生的規律和臨床錶現,提示臨床註意鑑測其不良反應,避免嚴重後果.方法 對39例頭孢唑肟鈉註射劑引起的不良反應進行統計和分析.結果 女22例,男17例,女性多于男性;患者年齡在0~50歲之間,其中10歲以下兒童髮生率最高,為46.15%;靜脈滴註給藥38例(97.44%),肌內註射給藥1例(2.56%);頭孢唑肟鈉註射劑的主要不良反應是過敏反應(66.67%),此外還可引起過敏性休剋、呼吸繫統損害等較少見的、嚴重的不良反應.結論 要閤理使用頭孢唑肟鈉註射劑,避免和減少不良反應的髮生.
목적 통과대39례두포서우납주사제인기적불량반응보고진행분석,탐토두포서우납주사제불량반응발생적규률화림상표현,제시림상주의감측기불량반응,피면엄중후과.방법 대39례두포서우납주사제인기적불량반응진행통계화분석.결과 녀22례,남17례,녀성다우남성;환자년령재0~50세지간,기중10세이하인동발생솔최고,위46.15%;정맥적주급약38례(97.44%),기내주사급약1례(2.56%);두포서우납주사제적주요불량반응시과민반응(66.67%),차외환가인기과민성휴극、호흡계통손해등교소견적、엄중적불량반응.결론 요합리사용두포서우납주사제,피면화감소불량반응적발생.
Objective To explore the incidence and clinical manifestations of ceftizoxime sodium-associated adverse reactions by analyzing the reports of adverse reactions caused by 39 cases of ceftizoxime sodium injections, this thesis aims at exploring the law of adverse reactions and of ceftizoxime sodium injection, reminding clinical treatment to monitor the adverse reactions to avoid serious consequences.Methods The adverse reactions caused by ceftizoxime sodium injections in 39 patients were analyzed statisticcally. Results More adverse reactions occurred in females than in males( 22 vs 17 ). The patients was 0 to 50 years old, mostly children younger than 10 ( 46.15% ). 38 patients ( 97.44% ) were due to intravenous drip and one ( 2.56% ) due to tointramuscular injection. The main adverse reaction was allergic reaction(66.67% ) in addition, other rare and severe adverse reactions including anaphylactic shock and respiratory damage could developed. Conclusions Ceftizoxime sodium injections should be rationally used to avoid or reduce the incidence of adverse reactions.